Zobrazeno 1 - 10
of 70
pro vyhledávání: '"G, Vanden Bussche"'
Publikováno v:
Anaesthesia. 43:270-273
Sufentanil, a short-acting and potent narcotic agent, was studied as a premedicant administered by the nasal route. A total dose of 5 micrograms appeared to be too low, while either 10 or 20 micrograms was very effective in producing sedation. Side e
Autor:
A. Raeymaekers, G. Vanden Bussche, Gerard Charles Sanz, E. Snoeck, R. De Coster, J. Bruynseels, W. Wouters, H. Vanden Bossche, M.-C. Coene, P. Van Rooy, G. Willemsens, Eddy Jean Edgard Freyne, P. A. J. Janssen
Publikováno v:
The Prostate. 16:345-357
R 75251, a new imidazole derivative, inhibited the conversion of androgens to estrogens, of progestins to androstenedione and testosterone, and of 11-deoxycorticosterone to corticosterone in human placenta microsomes, subcellular fraction of rat test
Autor:
M. M.-L. Janssens, G. Vanden Bussche
Publikováno v:
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 21
The new H1-receptor antagonist levocabastine is the most potent antihistamine available, as shown in classical animal tests for antihistamine activity. Its effects also are very specific, with doses as high as 40,000 times the effective antihistamine
Autor:
G. Vanden Bussche, F. Roeckaerts
Publikováno v:
Angiology. 31:833-845
In 4 placebo-controlled double-blind studies of patients suffering from venous insufficiency—defined as the presence of varicose veins combined with a range of subjective symptoms and presence of venous ulcers—flunar— izine was statistically si
Publikováno v:
Anaesthesia. 40:634-638
An open pilot study was undertaken to evaluate the analgesic properties of epidurally administered sufentanil in the early postoperative period. After orthopaedic surgery of the lower extremity, four different groups of five adult patients each recei
Autor:
F. W. H. M. Merkus, F. W. J. Gribnau, Th. Thien, Hans W. Louwerenburg, J. Herre Kingma, Wiek H. van Gilst, A. Jacob Six, Pieter de Graeff, Harry Wesseling, J. R. BoeLaert, M. L. Schurgers, E. G. Matthys, F. Belpaire, R. F. Daneels, M. J. de Cre, M. G. Boqaert, P. C. D'Haese, G. A. Verpooten, L. V. Lamberts, L. Liang, M. E. de Broe, P. H. E. M. de Meijer, F. G. M. Russel, A. J. M. Russel, C. A. M. van Ginneken, B. M. van Liedekerke, W. E. Lambert, M. A. Yousouf, J. E. de Roose, A. P. de Leenheer, W. Lambert, J. de Bersaques, L. Vanneste, A. de Leenheer, S. de Marie, G. Slaghuis, P. M. Rozing, H. Mattie, F. G. J. Poelma, H. W. Hilbers, A. C. A. Jansen, J. J. Tukker, P. Augusti, N. Verbeke, A. van Peer, E. Snoeck, J. Heykants, J. Bruynseels, J. Peeters, W. Amery, V. Rogiers, Y. Vandenberghe, M. Comet, A. Callaerts, W. Sonck, A. Guillouzo, A. Vercruysse, P. van Rooy, N. Rombaut, G. vanden Bussche, A. C. I. T. L. Tan, T. L. Th. A. Jansen, E. F. S. Termond, P. W. C. Kloppenborg, Th. J. Benraad, V. van de Velde, R. Woestenbprghs, W. A. J. J. Hermens, S. G. Romeijn, M. J. M. Deurloo, G. Musch, D. L. Massart, M. van Hengstum, J. Festen, W. van den Broek, F. Corstens, C. Beurskens, M. Hankel, M. de Smet, S. J. P. van Belle, J. de May, G. A. Storme, P. J. K. Kuppen, H. Schuitemaker, L. J. van't Veer, A. T. van Oosterom, P. I. Schrier, E. A. de Bruijn, C. H. de Pooter, U. R. Tjaden, H. van Slooten, H. P. Roelevink, E. Smit, E. G. E. de Vries, J. Ijmker, D. R. A. Uges, M. Moors, K. Mertens, A. van Hecken, I. de Lepeleire, R. Verbesselt, T. B. Tjandra-Maga, P. J. de Schepper, P. J. M. Guelen, T. J. Jansen, W. P. Vrijhof, D. de Vos, S. Scharpé, R. Verkerk, N. Lsmeire, I. F. Zijlstra, F. M. Haaijer-Ruskamp, D. Post, P. F. Reddingius, H. Wesseling, H. C. H. Wollersheim, A. H. van den Meiracker, A. J. Man in 't Veld, P. Admiraal, F. Boomsma, F. Derkx, M. A. D. H. Schalekamp, D. F. Schoors, A. G. Dupont, F. Claessen, J. Reljenga, J. W. M. Lenders, Th. Thlen, G. Laekeman, L. Muylle, A. van Hoydonck, A. G. Herman, M. E. Peetermans
Publikováno v:
Pharmaceutisch Weekblad. 10:291-299
Publikováno v:
Human toxicology. 6(6)
1 Six healthy volunteers took part in a 2-week haemodynamic safety study of astemizole. 2 They were given 30 mg daily (3 x 10 mg tablets) for the first 3 days and 10 mg daily for the next 12 consecutive days. 3 Heart rate, blood pressure, ECG and sys
Publikováno v:
European journal of anaesthesiology. Supplement. 1
Owing to the rapid blood:brain equilibration and the short duration of action, alfentanil is well suited for use in infusion techniques. A pharmacokinetic basis is given for alfentanil infusion schemes in patients undergoing routine surgery. Practica
Publikováno v:
International journal of clinical pharmacology, therapy, and toxicology. 24(5)
Four patients undergoing hemodialysis because of terminal renal insufficiency have taken 10 mg of astemizole on two consecutive days. The elimination was followed for 7 days and was found not to be delayed. During dialysis no decrease of the plasma l
Publikováno v:
Annals of allergy. 58(3)
From clinical-pharmacologic and clinical data involving over 2,800 patients, astemizole appears to be a very effective and well-tolerated antihistamine. It is superior to placebo and commonly used antihistamines for the relief of rhinitis, particular